• Sales: € 2.77 billion, + 16 % at actual rates, + 22 % in constant currency
• EBIT: € 380 million, + 31 % at actual rates, + 37 % in constant currency
• Net income: € 93 million, + 43 % at actual rates, + 48 % in constant currency

• All business segments in line with forecast
• Continued strong sales and earnings growth
  Fresenius ProServe to focus on hospital business – agreement reached to sell Pharmatec to Robert Bosch GmbH

Outlook for 2007 confirmed
Based on the Group's strong financial results in the first quarter, Fresenius fully confirms its positive outlook for 2007 issued at the end of February. Group sales are expected to grow by 8 to 10 % in constant currency. Net income is expected to increase by 20 to 25 % in constant currency. Further margin improvements in all business segments are expected to contribute to this growth.

Sales – Very good organic growth
Group sales increased by 16 % to € 2,767 million in the first quarter of 2007 (Q1 2006: € 2,388 million). Organic growth was 7 %. Acquisitions contributed 17 %, in particular Renal Care Group which was consolidated for the first time as from the second quarter of 2006. Divestitures reduced sales by 2 %. Currency translation effects had a negative impact of 6 %. This was mainly attributable to the average dollar depreciation of 9 % against the euro in the first quarter of 2007 compared to previous year's period.

In North America sales grew significantly due to the Renal Care Group consolidation and an excellent organic growth rate of 9 %. In Europe sales increased by 8 % in constant currency, with organic growth of 4 %. Strong growth rates were achieved in the emerging markets with organic growth of 12 % in Asia-Pacific, 10 % in Latin America and 25 % in Africa.

Excellent earnings growth
EBITDA increased by 34 % in constant currency and by 27 % at actual rates to € 479 million (Q1 2006: € 377 million). Group operating income (EBIT) increased by 37 % in constant currency and by 31 % at actual rates to € 380 million (Q1 2006: € 291 million). This growth was driven by the successful operating results in all business segments. The Group's EBIT margin improved to 13.7 % (Q1 2006: 12.2 %).

Group net interest was € -95 million (Q1 2006: € -84 million, incl. one-time expenses of € 25 million for the early refinancing of Group debt). This increase was primarily driven by debt financing of the Renal Care Group acquisition as from Q2 2006.

The tax rate further improved to 36.1 % from 36.7 % in Q1 2006.

Minority interest was € 89 million (Q1 2006: € 66 million), of which 93 % was attributable to the minority interest in Fresenius Medical Care.

Group net income grew strongly by 48 % in constant currency and by 43 % at actual rates to € 93 million (Q1 2006: € 65 million, incl. one-time expenses of € 11 million).

Earnings per ordinary share were € 0.60 and earnings per preference share were € 0.60 (Q1 2006 adjusted for the share split in February 2007: ordinary share € 0.43 and preference share € 0.43). This is an increase of 40 %.

Investments at high level
Fresenius Group spent € 140 million for property, plant and equipment and intangible assets (Q1 2006: € 100 million). Acquisition spending was € 155 million (Q1 2006: € 3,290 million).

Strong cash flow
Operating cash flow increased by 54 % to € 287 million (Q1 2006: € 186 million), mainly driven by the strong increase in earnings. Cash flow before acquisitions and dividends increased to € 155 million (Q1 2006: € 91 million). The free cash flow after acquisitions (€ 63 million) and dividends (€ 4 million) was € 88 million (Q1 2006: € -3,199 million).

Solid balance sheet structure
Total assets increased in constant currency and at actual rates by 1 % to € 15,159 million (December 31, 2006: € 15,024 million). Current assets increased by 1 % to € 4,165 million (December 31, 2006: € 4,106 million). Non-current assets were € 10,994 million (December 31, 2005: € 10,918 million).

Shareholders' equity including minority interest grew by 3 % to € 5,873 million (December 31, 2006: € 5,728 million). The equity ratio (including minority interest) was 38.7 % (December 31, 2006: 38.1 %).

The Group's debt was € 5,778 million (December 31, 2006: € 5,872 million). Given the excellent earnings growth and a strong cash flow the net debt/EBITDA ratio improved to 2.8 as of March 31, 2007 (December 31, 2006: 3.0).

Employees
As of March 31, 2007, the Group had 107,348 employees (December 31, 2006: 104,872), an increase of 2 %.

Fresenius Biotech
Fresenius Biotech develops innovative therapies with trifunctional antibodies for the treatment of cancer as well as cell therapies for the treatment of the immune system. In the field of polyclonal antibodies, Fresenius Biotech has successfully marketed ATG-Fresenius S for many years. ATG-Fresenius S is an immunosuppressive agent used to prevent and treat graft rejection following organ transplantation.

In March 2007, encouraging results in the non-ovarian cancer patient stratum of a phase II/III pivotal study on malignant ascites were published, including treatment data of 129 patients. The results showed a clear advantage of the therapy with the trifunctional antibody removab® over a therapy with puncture alone. Data on overall survival of all 258 patients for both strata of the study are expected in the second quarter of 2007.

The Phase II studies with the antibody rexomun® to treat breast cancer and with the antibody removab® to treat gastric cancer are ongoing. These studies started in March 2006 and June 2006 respectively. A phase II study with removab® is due to start in Europe in the first half of 2007 for the treatment of patients with ovarian cancer.

Fresenius Biotech's operating income (EBIT) was € -11 million in Q1 2007. For 2007, Fresenius Biotech expects an EBIT of approximately € -50 million (2006: € -45 million).

The Business Segments

Fresenius Medical Care
Fresenius Medical Care is the world's leading provider of services and products for patients with chronic kidney failure. As of March 31, 2007, Fresenius Medical Care was serving 169,216 patients in 2,194 dialysis clinics.

• Excellent sales increase and high organic growth in all regions
• Continued strong earnings growth
• Outlook for 2007 fully confirmed

Fresenius Medical Care achieved strong sales growth of 33 % to US$ 2,321 million (Q1 2006: US$ 1,747 million), mainly driven by the excellent organic growth of 9 % and by the consolidation of Renal Care Group. Sales in dialysis care increased by 38 % to US$ 1,760 million (Q1 2006: US$ 1,273 million). In dialysis products Fresenius Medical Care achieved sales of US$ 560 million (Q1 2006: US$ 474 million), an increase of 18 %.

In North America Fresenius Medical Care's sales increased by 37 % to US$ 1,637 million (Q1 2006: US$ 1,194 million). Sales outside North America ("International") grew by 24 % (17 % in constant currency) to US$ 684 million (Q1 2006: US$ 553 million). This was primarily driven by the positive operating performance in Europe and the Asia-Pacific region.

Fresenius Medical Care increased EBIT by 50 % to US$ 365 million (Q1 2006: US$ 244 million), the EBIT margin was 15.7 % (Q1 2006: 14.0 %). Net income increased by 38 % to US$ 160 million (Q1 2006: US$ 116 million, incl. one-time expenses of US$ 9 million).

For the full year 2007, Fresenius Medical Care confirms its outlook and expects sales of about US$ 9.4 billion. The net income is expected to be between US$ 675 million and US$ 695 million.

For further information, please see Fresenius Medical Care's press release at www.fmc-ag.com.

Fresenius Kabi
Fresenius Kabi offers infusion therapies and clinical nutrition for seriously and chronically ill patients in the hospital and out-patient environments. The company is also a leading provider of transfusion technology products.

• Very good organic sales growth
• Continued strong earnings development
• Outlook for 2007 fully confirmed

In the first quarter of 2007, Fresenius Kabi's sales increased by 4 % to € 483 million (Q1 2006: € 466 million). Currency translation effects had an impact of -3 %. This was mainly due to the depreciation of the currencies in China, Brazil, Mexico and Canada against the euro. Organic growth was 6 %, acquisitions contributed 1 % to growth.

Organic sales in Europe (excluding Germany) increased by 5 %. In Germany organic sales decreased by 1 %. Outside Europe, Fresenius Kabi achieved organic sales growth of 22 % in the Asia-Pacific region. In Latin America organic sales growth was 7 % and in other regions 8 %.

Fresenius Kabi achieved a very good EBIT growth, with an increase of 13 % to € 77 million (Q1 2006: € 68 million). The EBIT margin was 15.9 % (Q1 2006: 14.6 %). Net income rose by 62 % to € 42 million (Q1 2006: € 26 million, including one-time expenses for early debt refinancing of € 8 million).

Fresenius Kabi confirms its outlook for the full year 2007. The company expects a further successful sales and earnings performance. Organic sales growth is projected to be 6 to 8 %. Continued strong sales growth is anticipated from the regions outside Europe. Based on the positive sales projection and further manufacturing and logistics improvements Fresenius Kabi expects an EBIT margin of 16.0 to 16.5 % in 2007.

Fresenius ProServe
Fresenius ProServe is a leading German hospital operator with 55 facilities. Moreover, the company offers engineering and services for hospitals and other health care facilities.

• Strong operating results achieved
• Divestiture of Pharmaplan finalized, agreement signed to sell Pharmatec to Robert Bosch GmbH
• Outlook for 2007 fully confirmed

Fresenius ProServe's sales grew by 9 % to € 521 million in Q1 2007 (Q1 2006: € 476 million). Organic growth was 3 %. EBIT increased by 20 % to € 36 million (Q1 2006: € 30 million).

Sales in hospital operations (HELIOS Kliniken Group) increased by 15 % to € 439 million (Q1 2006: € 383 million). The sales growth is mainly attributable to the acquisition of HUMAINE Kliniken, which was consolidated as of July 1, 2006. HELIOS also achieved strong organic growth of 3 %. EBIT increased by 19 % to € 32 million, the EBIT margin was 7.3 % (Q1 2006: € 27 million and 7.0 %).

In 2007, HELIOS continued its growth strategy in the German hospital market. The company acquired two hospitals in North Rhine-Westphalia with approximately 330 beds and revenues of € 32 million in 2006. A further hospital was acquired on Lake Constance with 170 beds and revenues of € 22 million in 2005 and was consolidated as from January 1, 2007. In addition, the option to acquire the outstanding equity stake (40 %) in HUMAINE Kliniken GmbH was exercised.

Sales in the engineering and services business was € 82 million (Q1 2006: € 93 million). The decrease was due to the sale of Pharmaplan, which was deconsolidated as of January 1, 2007. Organic growth was 2 %. EBIT of € 5 million was at previous year's level. Order intake continued to develop very positively and increased by 18 % to € 78 million (Q1 2006: € 66 million). Order backlog was € 431 million (December 31, 2006: € 428 million).

On May 1, 2007, Fresenius ProServe agreed to sell its subsidiary Pharmatec to Robert Bosch GmbH. With the divestiture of Pharmaplan and Pharmatec, Fresenius ProServe completes its strategy to focus on its business with hospitals and other healthcare facilities. Pharmatec manufactures high quality pure steam, pure water and sterilization equipment for the pharmaceutical industry. In 2006, the company had sales of about € 30 million. The transaction requires antitrust approval. Fresenius ProServe anticipates the closing of the transaction mid-year 2007.

Fresenius ProServe confirms its outlook for the full year 2007 and expects organic sales growth of 2 to 3 %. EBIT is expected to increase to € 160 to 170 million.

Conference Call
As part of the publication of the first quarter 2007 results, a conference call will be held on May 2, 2007 at 2.00 p.m. CEDT (8.00 a.m. EDT). We invite all interested to follow the conference call over our website. Following the conference, a recording of the call will be available.

Fresenius Group in Figures

• Consolidated statement of income (US GAAP) (unaudited)
• Key figures of the balance sheet (US GAAP) (unaudited)
• Cash flow statement (US GAAP) (unaudited)
• Segment reporting by business segment Q1/2007 (US GAAP) (unaudited)

see PDF-file

At the Annual General Meeting in Frankfurt, Germany, a large majority of Fresenius Medical Care's shareholders approved the Management and Supervisory Boards' proposal for a share split in the ratio of 1:3. The corresponding resolution was supported by far more than 99 per cent of the represented ordinary share capital. The share split will become effective upon the registration in the commercial register, which is expected in the third quarter of 2007.

After the share split, every holder of an ordinary share will hold three ordinary shares and every holder of a preference share will hold three preference shares. As a result of the share split, the share price will be reduced arithmetically to one third without affecting the overall value for shareholders. The share split is intended to promote trading activity in Fresenius Medical Care shares and to increase the shares' attractiveness for a broader group of investors. The strong performance of the Company in recent years has led to a sharp increase in the share price which is currently one of the highest in Germany's DAX index.

Through a conversion of capital reserves, the subscribed capital of Fresenius Medical Care AG & Co. KGaA is first increased to € 295.2 million. The subscribed capital is then divided into 291,449,373 ordinary shares and 3,720,522 preference shares. The new amount of the subscribed capital will then be € 1.00 per share.
In addition, shareholders of Fresenius Medical Care approved the tenth consecutive dividend increase. Ordinary shareholders will receive € 1.41 per share (prior year: € 1.23) and preference shareholders will receive € 1.47 (prior year: € 1.29). Shareholders discharged Management and Supervisory Board with a large majority of far more than 99 per cent.

At the Annual General Meeting, 74.24 per cent of the ordinary share capital and 5.33 per cent of the preference share capital was represented. Only ordinary shareholders were entitled to vote.

###

Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1,500,000 individuals worldwide. Through its network of 2,194 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 169,216 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME, FME3) and the New York Stock Exchange (FMS, FMS/P).

For more information about Fresenius Medical Care visit the Company's website at www.fmc-ag.com.

Following the company's very strong 2006 financial results, Fresenius expects to significantly expand its sales and earnings in 2007. At the company's Annual General Meeting in Frankfurt, Germany, Dr. Ulf M. Schneider, Chairman of the Management Board, said that "We have had an excellent start into the fiscal year 2007 and confirm our guidance for the full year." According to the company's outlook released in February, Fresenius expects Group sales to increase on a currency-adjusted basis by 8 to 10% in 2007 while net income is expected to grow by 20 to 25%.

Referring to the company's mid-term goals, Dr. Schneider stated: "We intend to continue our steady growth as we look towards the year 2010. The Management Board has set a mid-term target we call 15/15. We are targeting revenues of €15 billion and we expect to achieve an EBIT margin of 15% by the year 2010. We plan to achieve this target through sales and earnings growth in all business segments. In addition, we will be looking to strengthen our business segments through small and mid-sized acquisitions."

During the Annual General Meeting Fresenius shareholders unanimously approved a 15 percent increase in dividends, the 14th consecutive increase. Holders of ordinary shares will receive €0.57 per share (2005: €0.49, after adjusted for the share split) and holders of preference shares will receive €0.58 (2005, €0.50, after adjusted for the share split). A total of €88.8 million (2005: €75.8 million) will be distributed as dividends.

90.88 percent of the ordinary share capital and 8.73 percent of the preference share capital was represented at the Annual General Meeting. Shareholders approved the actions of the Management and Supervisory Boards with an overwhelming majority (99.99 percent).

# # #

Fresenius is a health care group with international operations, providing products and services for dialysis, hospital and the ambulatory medical care of patients. In 2006 group sales were about € 10.8 billion. On December 31, 2006 the Fresenius Group had 104,872 employees worldwide.

Fresenius AG today announced that it will reorganize its hospital business effective January 1, 2008. The current business segment Fresenius ProServe will be replaced by the two new business segments Fresenius HELIOS and Fresenius VAMED which so far have formed Fresenius ProServe. Following the reorganization, the Fresenius Group will have four business segments – Fresenius Medical Care, Fresenius Kabi, Fresenius HELIOS and Fresenius VAMED.

This step underlines the growing importance of the hospital operations business (HELIOS) and the engineering and services business for hospitals (VAMED). In future, these business segments will be run independently and be directly represented in Fresenius AG's Management Board.

In 2006, HELIOS Kliniken achieved revenues of € 1.67 billion. Operating income was € 133 million. HELIOS owns 58 clinics with 15,800 beds. The company will continue to operate under its original name HELIOS Kliniken GmbH. VAMED had revenues of € 392 million in 2006. Operating income was € 24 million. In addition, VAMED handled approximately € 350 million in third-party revenues through management contracts. VAMED has a strong international presence and managed healthcare projects in approximately 80 countries. The company will also continue to operate under its original name VAMED AG.

The following shows the new group structure:

As part of the new organizational structure, Dr. Francesco De Meo (43) and Dr. Ernst Wastler (48) will join the Management Board of Fresenius AG effective January 1, 2008. Francesco De Meo will be responsible for the business segment Fresenius HELIOS. Ernst Wastler will be in charge of the business segment Fresenius VAMED.

Since July 1, 2000, Dr. Francesco De Meo has served as a managing director of HELIOS Kliniken GmbH with responsibility for personnel and legal affairs. He will succeed Ralf Michels as CEO of HELIOS Kliniken GmbH effective January 1, 2008. Ralf Michels will then become a member of the Supervisory Board of HELIOS Kliniken GmbH.

Ernst Wastler has served as CEO of VAMED AG since July 1, 2001. He joined the company in 1984 and has contributed significantly to the international expansion of VAMED.

As a result of the reorganization, Andreas Gaddum, member of the Management Board of Fresenius AG and responsible for the business segment Fresenius ProServe, will leave the company by mutal agreement effective December 31, 2007. Andreas Gaddum has played a key role in focussing Fresenius ProServe on the hospital business.

In addition, Fresenius announced the appointment of Dr. Jürgen Götz (43) as member of the Management Board of Fresenius AG effective July 1, 2007. Jürgen Götz will be responsible for legal, compliance and personnel affairs. He also will assume the position as Labor Relations Director from Stephan Sturm who will continue to serve as CFO of Fresenius AG.

"The new organizational structure sets the stage for the focused expansion of Fresenius HELIOS and Fresenius VAMED within our group. In addition, we reduce the number of management layers and increase the transparency of the hospital business for our investors. I would like to thank Andreas Gaddum for his significant contributions and his achievements in Fresenius ProServe's strategic realignment. At the same time, I am looking forward to working with Jürgen Götz, Francesco De Meo and Ernst Wastler in the Fresenius Management Board. They have done an outstanding job in their current assignments and are superbly qualified to be part of our senior leadership team as we take the company to the next level", commented Dr. Ulf M. Schneider, Chairman of the Management Board of Fresenius AG.

The Company expects no restructuring costs to result from these organizational changes. Fresenius Group will adjust its financial reporting to the new structure in the first quarter of 2008.

# # #

Fresenius is a health care group with international operations, providing products and services for dialysis, hospital and outpatient medical care. In 2006 group sales were about € 10.8 billion. On March 31, 2007 the Fresenius Group had 107,348 employees worldwide.

Fresenius Medical Care AG & Co. KGaA ("the Company"), the world's largest provider of Dialysis Products and Services, today announced that the share split with capital increase from the Company's funds approved by the Ordinary General Meeting on May 15, 2007, will become effective on June 18, 2007. On the same day, the shares will be traded "ex split" and the shareholders' deposits will be adapted to the new number of shares. Every holder of an ordinary share now holds three ordinary shares and every holder of a preference share holds three preference shares. As a result of the share split, the price level will be reduced arithmetically without affecting the overall value for shareholders.

The Fresenius Medical Care shares will continue to trade under ISIN DE0005785802 (ordinary share) and ISIN DE0005785836 (preference share).

The subscribed capital of Fresenius Medical Care AG & Co. KGaA now amounts to €295,422,342.00, divided into 291,701,520 ordinary shares and 3,720,822 preference shares.

For American Depositary Share (ADS) Investors:
Fresenius Medical Care shares are traded on the New York Stock Exchange (NYSE) in the form of ADSs under the ISIN US3580291066 (ordinary share) and ISIN US3580292056 (preference share). Before the share split 3 ADSs represented 1 underlying Share. Upon effectiveness of the share split, the ratio between the ordinary and preference ADS and the underlying ordinary and preference shares is now 1:1, meaning that one Fresenius Medical Care ordinary or preference ADSs is the equivalent of one Fresenius Medical Care ordinary or preference share.

For more information about Fresenius Medical Care visit the Company's website at www.fmc-ag.com.

# # #

Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1,500,000 individuals worldwide. Through its network of 2,194 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 169,216 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME, FME3) and the New York Stock Exchange (FMS, FMS/P).

Fresenius Medical Care AG & Co. KGaA ("the Company") (Frankfurt Stock Exchange: FME, FME3) (NYSE: FMS, FMS-p), the world's largest provider of Dialysis Products and Services, today announced that it intends to sell approximately US$ 500 million senior unsecured notes. The notes will be offered mainly to US institutional investors. Proceeds from the offering will be used to reduce indebtedness under the Company's senior secured bank credit facility and other, short-term debt, and for general corporate purposes.

The proposed offering will not be registered under the Securities Act of 1933, but will be offered in the United States pursuant to an exemption from registration under Rule 144A as well as outside the United States under Regulation S. The Company expects completion of the offering at the beginning of July 2007.

# # #

Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1,500,000 individuals worldwide. Through its network of 2,194 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 169,216 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME, FME3) and the New York Stock Exchange (FMS, FMS/P).

For more information about Fresenius Medical Care visit the Company's website at www.fmc-ag.com.

Most dialysis patients have a significantly better chance of survival if they are treated with high-flux dialyzers rather than low-flux dialyzers. This is the conclusion of a new international study conducted under the direction of the Italian renal specialist Prof. Francesco Locatelli from the Alessandro Manzoni Hospital in Lecco.

The results of the study were presented last weekend during the European Dialysis and Transplantation Association/European Renal Association (EDTA/ERA) Congress in Barcelona. The study showed that dialysis patients with a low albumin concentration in their blood that were treated with high-flux dialyzers had a 37% lower mortality risk during the three to seven-and-a-half years of the study than those that were treated with low-flux dialyzers. Depending on the country, 56% to 85% of dialysis patients have a low albumin concentration in their blood (four grams per deciliter or less).

The study was conducted over seven-and-a-half years in nine European countries. The 738 patients involved were treated three times a week. Half of the patients received treatment with high-flux dialyzers – predominantly dialyzers from Fresenius Medical Care. The other half received therapy with low-flux dialyzers.

This is the first time a prospective randomized clinical study scientifically proves that treatment with high-flux dialyzers reduces the mortality risk of patients with severe chronic kidney disease. Indications of a lower mortality risk first appeared in the mid-90s.

Specialists attribute the increased survival rates from high-flux dialyzers to a more efficient filtering of larger uremic toxins from the blood. High-flux membranes have a greater water permeability and pores that are two-and-a-half times larger than low-flux membranes. The filtering capabilities of high-flux membranes are closer to the natural kidney function and allow the body to remove large amounts of liquids and toxic uremic substances in a short period of time. High-flux dialyzers can also help maintain any remaining kidney function for a longer period of time.

High-flux dialyzers have the most technically advanced membranes. Their use is increasing worldwide and, in many countries, more than 60% of the patients are treated with high-flux dialyzers. "The positive results of the new study validate our efforts to offer innovative dialysis products such as our high-flux dialyzers with Helixone membranes so that dialysis patients can look toward the future with more confidence. We expect demand for high-flux dialyzers to continue to increase. And we are proud that the majority of the patients in the study's high-flux-group were treated with our dialyzers," said Dr. Emanuele Gatti, Fresenius Medical Care Chief Executive Officer for Europe, Latin America, Middle East and Africa.

# # #

Helixone is a registered trademark of Fresenius Medical Care.

Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1,500,000 individuals worldwide. Through its network of 2,194 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 169,216 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME, FME3) and the New York Stock Exchange (FMS, FMS/P).

For more information about Fresenius Medical Care visit the Company's website at www.fmc-ag.com.

Fresenius Medical Care AG & Co. KGaA ("the Company"), the world's largest provider of Dialysis Products and Services, today announced the pricing of Senior Notes due 2017 in the amount of US$ 500 million. The coupon will be 6 7/8%. Proceeds will be used to reduce indebtedness under the Company's senior secured bank credit facility and other, short-term debt.

The Senior Notes will be issued by FMC Finance III S.A., a wholly-owned subsidiary of the Company, and will be guaranteed on a senior basis jointly and severally by the Company, Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care Deutschland GmbH.

Lawrence A. Rosen, Chief Financial Officer of Fresenius Medical Care, commented: "We are pleased to have successfully completed the company's first senior unsecured bond offering. Investors have clearly recognized our sustainable financial strength and are confident in the future of the industry and Fresenius Medical Care."

The notes were not registered under the Securities Act of 1933, but were offered in the United States pursuant to an exemption of registration under Rule 144 A, as well as outside the United States under Regulation S. The notes may not be offered or sold in the United States without registration or an applicable exemption from the registration requirements.

# # #

Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1,500,000 individuals worldwide. Through its network of 2,194 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 169,216 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME, FME3) and the New York Stock Exchange (FMS, FMS/P).

For more information about Fresenius Medical Care visit the Company's website at www.fmc-ag.com.

Fresenius today announced that the conversion of Fresenius AG into a European Company (Societas Europaea) took effect on July 13, 2007 with the entry of Fresenius SE in the commercial register of the Bad Homburg municipal court. The Company's Supervisory Board will continue to have twelve members, divided equally between employee and shareholder representatives.

For the first time, employees from other European countries outside of Germany will have Board representation with one member representing Austrian employees and another representing Italian employees. The six shareholder representatives for the new Supervisory Board were already appointed as part of the December 4, 2006 Extraordinary General Meeting that had approved the statutes of Fresenius SE. During that Meeting, a vast majority of 99.99 percent of the ordinary share capital represented had approved the conversion.

An SE is a public limitedliability company under European law. The SE particularly facilitates an open and international corporate culture while reflecting Fresenius' global orientation. With the exception of the composition of the Supervisory Board, the conversion will have no effect on the Company's management structure.

# # #

Fresenius is a health care group with international operations, providing products and services for dialysis, hospital and outpatient medical care. In 2006 group sales were about € 10.8 billion. On December 31, 2006 the Fresenius Group had 107,348 employees worldwide.

Fresenius today announced that further secondary endpoint data from a phase II/III study with removab® (catumaxomab) in patients with malignant ascites confirm clear benefits for patients treated with the antibody. Trial data show that removab significantly increases time to tumor progression and has a positive influence on overall survival time. Moreover, a prolonged interval between punctures was seen in the removab group compared to the control group and this effect was also observed beyond the end of study.

The results of the randomized study include treatment data from 258 patients with malignant ascites caused by various cancers. Most patients had late-stage disease with a median life expectancy of two to three months. The primary endpoint of the study had already demonstrated that patients receiving removab had a four-fold increased puncture-free survival over a therapy with puncture alone (median 46 vs. 11 days, p<0.0001). The median time to the first therapeutic puncture, a key secondary endpoint, improved to 77 days in the removab group versus 13 days in the control group (p<0.0001). In contrast to the primary endpoint, patients who died before the next puncture were not included in this metric.

There was a clear difference between the two study arms with regard to the time to progression (TTP) of the underlying cancer. The median TTP (secondary endpoint) for the 170 patients treated with removab was 111 days, compared to 35 days for the 88 patients of the control group (p<0.0001). In the subgroup of patients with ascites from ovarian cancer, removab-treated TTP was also 111 days, compared to patients in the control group with 35 days (p=0.0002). In addition, patients with other primary cancers receiving removab also showed significant improvement in TTP, with a median of 110 days versus 34 days with puncture-therapy alone (p<0.0001).

A positive trend was also observed for overall survival. Median overall survival in the 170 patients in the removab group was 72 days, compared to 68 days of the 88 patients in the control group (p=0.0846). In a prospectively planned evaluation of 131 patients treated per protocol, a median survival advantage of 18 days was shown (removab: 86 days vs. control group: 68 days, p=0.0085). removab treatment also showed a positive influence on the overall survival of ovarian cancer patients with a median survival of 110 days over 81 days for patients receiving puncture-therapy alone (p=0.1543). In patients with gastric cancer (the largest subgroup among patients with cancers other than ovarian cancer) the median survival advantage was 27 days (71 vs. 44 days, p=0.0313).

After the primary end point of the study (puncture-free survival) was reached, the data showed that puncture intervals in patients treated with removab continued to be longer than those of the patients in the control group. The intervals between the first and second puncture were 26 and 24 days in the ovarian and non-ovarian cancer group treated with removab vs. 13 and 16 days in the control group.

Secondary study endpoints and other data collected from patients after reaching the primary endpoint confirm the benefit of removab treatment for this patient group at a late stage of their disease. Collectively, the study results further indicate the efficacy of removab in the treatment of various primary cancers. "The results of the phase II/III study show clear benefits for patients being treated with removab", says Dr. Bernhard Ehmer, President Fresenius Biotech. "The results also suggest a direct antitumor effect of the trifunctional antibody. Primary and secondary endpoints as well as post study data are consistent, and demonstrate a pronounced positive trend. They all point in the right direction and this gives us confidence in our ongoing development program for ovarian and gastric cancer."

Fresenius Biotech confirms that the submission for marketing authorization with EMEA is expected in late 2007.

# # #

About the phase II/III study with removab
A total of 258 patients with end-stage cancer and recurrent symptomatic malignant ascites, who either no longer responded to or could no longer be treated with chemotherapy, were enrolled in this study. 129 of the patients had ovarian cancer and 129 participants had other forms of epithelial tumors (gastric 51 %, breast 10 %, pancreatic 7 %, colorectal 6 %, others 26 %). Participants in the study were randomized in a 2:1 ratio, with 170 patients randomized to treatment with removab and 88 patients to puncture therapy alone. After reaching the study endpoint 51% of patients in the control arm were also given removab (crossover). removab was administered intraperitoneally at ascending doses through infusions, following paracentesis on days 0, 3, 7, and 10. 131 patients received all four infusions of 10, 20, 50, and 150 µg.

Mode of action of trifunctional antibody removab (catumaxomab)
The therapeutic objective of trifunctional antibodies is to generate a stronger immune reaction against tumor cells. removab has two different antigen binding sites: While one arm of the antibody recognizes and binds to T-cells, the other arm binds EpCAM (epithelial cell adhesion molecule) that is overexpressed in many types of epithelial cancers. Immune effector cells with Fc receptors (macrophages, monocytes, dendritic cells and natural killer cells) can also bind the Fc region of intact trifunctional antibodies. This simultaneous binding subsequently results in the costimulation and activation of T-cells and accessory cells, enabling the generation of a strong immune response against tumor cells. Preclinical data also suggest a potential long-lasting effect to prevent cancer recurrence. Apart from removab two other trifunctional antibodies targeting other cancer antigens are currently undergoing clinical development.

Trifunctional Antibodies
Trifunctional antibodies are proteins that activate different cell types of the immune system simultaneously and target tumor cells specifically. Trifunctional antibodies therefore are very effective in destroying cancer cells and show a therapeutic effect even at very low doses. They are being developed by TRION Pharma GmbH.

# # #

Fresenius Biotech is a company within the Fresenius health care group and is focused on the development and marketing of biopharmaceuticals in the fields of oncology, immunology and regenerative medicine. For further information please visit www.fresenius-biotech.com.

Fresenius is a health care group with international operations, providing products and services for dialysis, hospital and outpatient medical care. In 2006, group sales were about 10.8 billion. On March 31, 2007 the Fresenius Group had 107.348 employees worldwide.

Trion Pharma is a biopharmaceutical company that develops and produces trifunctional antibodies based on a globally patented technology platform together with Fresenius Biotech in Munich. For further information please visit www.trionpharma.de.

# # #

Glossary
Puncture-free survival period: Period between the last infusion (control group: day of the puncture) and the first subsequent necessary puncture or death, which ever occurs first.

TTP (Time to Progression): Time to progression is the length of time between treatment and further growth of the primary tumor or metastases.